A clinical trial evaluating insulin aspart has reached completed status as of August 14, 2026. The study, registered as NCT07600944, is titled "Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Insulin Aspart Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers." The trial phase is listed as not applicable. Its stated purpose was to compare the pharmacokinetic and pharmacodynamic biosimilarity of insulin aspart injections following a single subcutaneous dose in healthy volunteers.
The status update indicates the trial has finished, but no results have been reported alongside this update. This brief reflects only the completion status and trial description as registered. No efficacy, safety, or comparative outcome data are included here, as none were provided with this update.
Insulin aspart is an approved compound. Readers interested in study details, including sponsor information and any future results postings, can consult the official registry listing at the provided source link.
For general background on this compound, see the linked compound overview.